ARCA biopharma General Counsel Christopher Ozeroff to depart effective March 31, 2023

Oruka Therapeutics, Inc.

Christopher D. Ozeroff, Secretary, SVP and General Counsel, to leave ARCA biopharma effective March 31, 2023.
Departure is mutual and not due to any disagreement with the company's operations or policies.
Will receive severance payments and COBRA reimbursement under existing employment agreement, conditioned on release of claims.
No replacement for General Counsel has been announced.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Christopher D. Ozeroff

Secretary, Senior Vice President and General Counsel

ORKA · Oruka Therapeutics, Inc.

Effective: 2023-03-31
Filed: February 13, 2023, 6:59 PM ET

ARCA biopharma, Inc. (“ARCA” or the "Company") and Christopher D. Ozeroff, the Secretary, Senior Vice President and General Counsel of ARCA have mutually agreed to conclude Mr. Ozeroff’s employment effective March 31, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher D. Ozeroff departed as Secretary, Senior Vice President and General Counsel at Oruka Therapeutics, Inc..

Action: mutually agreed to conclude employment
Role: Secretary, Senior Vice President and General Counsel

Exact text from the filing

ARCA biopharma, Inc. (“ARCA” or the "Company") and Christopher D. Ozeroff, the Secretary, Senior Vice President and General Counsel of ARCA have mutually agreed to conclude Mr. Ozeroff’s employment effective March 31, 2023.

View on SEC.gov

Oruka Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-002622

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.